Key result
Among stable patients with end-stage renal disease receiving long-term hemodialysis via arteriovenous access, the prevalence of pulmonary hypertension was 26.74%.
Cohort (n=86)
There is a high prevalence (26.74%) of pulmonary hypertension among patients with ESRD receiving long-term hemodialysis, which does not appear to be driven by vascular access, anemia, or secondary hyperparathyroidism.
Answers are grounded in this paper and cite their sources.
Supports heightened vigilance for pulmonary hypertension in long-term hemodialysis; cross-sectional data leaves open causal drivers and outcome impact.
Pulmonary hypertension (PH) has been reported in hemodialysis (HD) patients, but data regarding its incidence and mechanisms are scarce. The aims of this study was to evaluate the prevalence of unexplained PH in long-term HD patients, and to examine some possible etiologic factors for its occurrence. The prevalence of PH was estimated by Doppler echocardiography in a cohort of 86 stable patients on HD via arteriovenous access for more than 12 months. All the patients underwent full clinical evaluation, chest radiography, and a standard 12-lead echocardiograph. Laboratory investigation included a mean of 12 months (serum calcium, phosphorus, parathormone (PTH), alkaline phosphatase, lipids, and hemoglobin). Pulmonary hypertension was defined as pulmonary artery systolic pressure >35 mmHg as determined by Doppler echocardiography using the modified Bernoulli equation. Pulmonary hypertension was detected in 23 patients (26.74%). Of those with PH, left ventricular hypertrophy was seen in 13 patients (56.52%), and valvular calcifications in 6 patients (26.08%). There were no significant differences between both groups with regard to age, sex, duration of dialysis, shunt location, and all the biological parameters of the study. The presence of PH was not related to the level of PTH, or the severity of other metabolic abnormalities. This study demonstrates a high prevalence of PH among patients with ESRD receiving long-term HD via surgical arteriovenous access. The role of the vascular access, anemia, or secondary hyperparathyroidism as the etiology of PH in HD patients did not hold in this study.
No takes yet. Share an insight, caveat, or question.
Tarrass et al. (2006) conducted a cohort in End-stage renal disease on hemodialysis (n=86). Long-term hemodialysis via arteriovenous access was evaluated on Prevalence of pulmonary hypertension (pulmonary artery systolic pressure >35 mmHg). Among stable patients with end-stage renal disease receiving long-term hemodialysis via arteriovenous access, the prevalence of pulmonary hypertension was 26.74%.
Synapse has enriched 10 related papers. Consider them for comparative context: